Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

A Novel Monoclonal Antibody Targeting a Large Surface of the Receptor Binding Motif Shows Pan-neutralizing SARS-CoV-2 Activity Including BQ.1.1 Variant

  • Campos-Mata, Leire de
  • Trinité, Benjamin
  • Modrego, Andrea
  • Tejedor, Sonia
  • Pradenas, Edwards
  • Rodrigo Melero, Natalia
  • Carlero, Diego
  • Marfil, Silvia
  • Pons-Grífols, Anna
  • Bueno-Carrasco, M. Teresa
  • Santiago, César
  • Tarrés-Freixas, Ferrán
  • Urrea, Víctor
  • Izquierdo-Useros, Núria
  • Riveira-Muñoz, Eva
  • Ballana, Ester
  • Pérez, Mónica
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carolis, Carlo
  • Arranz, Rocío
  • Blanco, Julià
  • Magri, Giulian
In the present study we report the functional and structural characterization of 17T2, a new highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody (mAb) isolated from a convalescent COVID-19 individual infected during the first wave of the COVID-19 pandemic. 17T2 is a class 1 VH1-58/κ3-20 antibody, derived from a receptor binding domain (RBD)-specific IgA memory B cell and developed as a human recombinant IgG1. Functional characterization revealed that 17T2 mAb has a high and exceptionally broad neutralizing activity against all SARS-CoV-2 spike variants tested, including BQ.1.1. Moreover, 17T2 mAb has in vivo prophylactic activity against Omicron BA.1.1 infection in K18-hACE2 transgenic mice. 3D reconstruction from cryogenic-electron microscopy (cryo-EM) showed that 17T2 binds the Omicron BA.1 spike protein with the RBD domains in up position and recognizes an epitope overlapping with the receptor binding motif, as it is the case for other structurally similar neutralizing mAbs, including S2E12. Yet, unlike S2E12, 17T2 retains its high neutralizing activity against all Omicron sublineages tested, probably due to a larger contact area with the RBD, which could confer a higher resilience to spike mutations. These results highlight the impact of small structural antibody changes on neutralizing performance and identify 17T2 mAb as a potential candidate for future therapeutic and prophylactic interventions., We acknowledge access to the cryo-EM CNB-CSIC facility in the context of the CRIOMECORR project (ESFRI-2019-01-CSIC-16) and we thank the staff of the Protein Technology Unity (CRG) for the help in protein production. This study was supported by the COVID-19 call grant from Generalitat de Catalunya, Department of Health (to GM), grant Miguel Servet research program (to GM), and partially funded by the crowdfunding initiative #joemcorono and the Fundació Glòria Soler (to JB). A.P-G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B 00698)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structure of the drug target ClpC1 unfoldase in action provides insights on antibiotic mechanism of action

  • Weinhäupl, Katharina
  • Gragera, Marcos
  • Bueno-Carrasco, M. Teresa
  • Arranz, Rocío
  • Krandor, Olga
  • Akopian, Tatos
  • Soares, Raquel
  • Rubin, Eric
  • Felix, Jan
  • Fraga, Hugo
The unfoldase ClpC1 is one of the most exciting drug targets against tuberculosis. This AAA+ unfoldase works in cooperation with the ClpP1P2 protease and is the target of at least four natural product antibiotics: cyclomarin, ecumicin, lassomycin, and rufomycin. Although these molecules are promising starting points for drug development, their mechanisms of action remain largely unknown. Taking advantage of a middle domain mutant, we determined the first structure of Mycobacterium tuberculosis ClpC1 in its apo, cyclomarin-, and ecumicin-bound states via cryo-EM. The obtained structure displays features observed in other members of the AAA+ family and provides a map for further drug development. While the apo and cyclomarin-bound structures are indistinguishable and have N-terminal domains that are invisible in their respective EM maps, around half of the ecumicin-bound ClpC1 particles display three of their six N-terminal domains in an extended conformation. Our structural observations suggest a mechanism where ecumicin functions by mimicking substrate binding, leading to ATPase activation and changes in protein degradation profile., The authors acknowledge the support of the European Union (EU) and Horizon 2020 through iNEXT-Discovery Proposal: 871037 (Access project PID: 15695) and the CRIOMECORR project (ESFRI-2019-01-CSIC-16) to the cryo-EM CNB-CSIC facility.” This work benefited from access to the Instruct Image Processing Center, an Instruct-ERIC centre. Financial support was provided by Instruct-ERIC (PID 15689)., Peer reviewed